Kintara Therapeutics Inc. - notizie pubblicate 163 - letture 2.064
KINTARA THERAPEUTICS INC.
Registration of Securities issued in Business Combination Transaction - Form S-4
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer kintara therapeutics inc. published th ...
KINTARA THERAPEUTICS INC.
Shareholder Meeting - Form 8-K
Item 5.08 shareholder director nominations on may 5, 2024, kintara therapeutics, inc. (the "company") scheduled its 2024 annual meeting of stockholders (the "2024 an ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 8-K
Tuhura biosciences to present its ifx-2.0 personalized cancer vaccine clinical trial results at the 2024 american society of clinical oncology (asco) annual meeting tampa, fl&s ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 425
Tuhura biosciences to present its ifx-2.0 personalized cancer vaccine clinical trial results at the 2024 american society of clinical oncology (asco) annual meeting tampa, fl&s ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement - Form 425
Kintara therapeutics and tuhura biosciences enter into definitive merger agreement • tuhura is planning to advance a single phase 3 trial for ifx-2.0 personalized cancer vaccine ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement - Form 8-K
Kintara therapeutics and tuhura biosciences enter into definitive merger agreement • tuhura is planning to advance a single phase 3 trial for ifx-2.0 personalized cancer vaccine ...
KINTARA THERAPEUTICS INC.
Registration Withdrawal - Form RW
Rw march 13, 2024 via edgar united states securities and exchange commission division of corporation finance 100 f street, n.e. washington, d.c. 20549 re: kintara therapeutics, inc ...
KINTARA THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01. other events. nasdaq compliance as previously reported, on september 20, 2023, kintara therapeutics, inc. (the "company") received a letter from the listing qu ...
KINTARA THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01. other events. nasdaq compliance as previously reported in kintara therapeutics, inc.'s (the "company") form 10-q for the quarterly period ended december 31, 20 ...
KINTARA THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01. other events. on february 22, 2024, kintara therapeutics, inc. (the "company") determined that it has concluded utilization of its at-the-market ("atm&quo ...
KINTARA THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01. other events. on february 22, 2024, kintara therapeutics, inc. (the "company") determined that it has concluded utilization of its at-the-market ("atm&quo ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update - Form 8-K
Kintara therapeutics announces fiscal 2024 second quarter financial results and provides corporate update san diego, february 14, 2024/prnewswire/ -- kintara therapeutics, inc. (na ...
KINTARA THERAPEUTICS INC.
Quarterly Report for Quarter Ending December 31, 2023 (Form 10-Q)
10-q united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☑quarterly report pursuant to section 13 or 15(d) of the securities exchange act ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer - Form 8-K
Kintara therapeutics announces initiation of rem-001 clinical trial for the treatment of cutaneous metastatic breast cancer - 15-patient open label study to confirm planned dose an ...
KINTARA THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01 other events. on december 18, 2023, kintara therapeutics, inc. (the "company") increased the maximum aggregate offering price of the shares of the company's com ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti